Health Care Flat Amid Deal Activity — Health Care Roundup
Health-care companies were flat amid deal activity.
Shares of Morphic Holdings rallied after drug giant Eli Lilly agreed to buy the biopharmaceutical company for $3.2 billion, paying a hefty premium for a firm that will bolster Lilly's immunology pipeline. Shares of other mid-sized biotech companies rose in sympathy, as traders anticipated a series of similar deals as Big Pharma companies -- flush with cash from obesity drugs and other products -- boost their drug pipelines via acquisitions.
Shares of both Eli Lilly and Danish rival Novo Nordisk have risen by more than 40% for the year to date because of the obesity-drug craze, which has furnished both companies with large war chests.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
July 08, 2024 17:28 ET (21:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 New Stocks to Buy With Catalysts for Future Gains
-
Markets Brief: Q2 Earnings Season Begins With the Banks
-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
3 Smaller-Company Stocks the Best Fund Managers Are Buying
-
SolarEdge Stock Is Down 74% In 2024. Is It a Buy or a Sell?
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries